Obesity Market Intelligence

Airfinity has launched the world’s most comprehensive data and analytics solution dedicated to the breakthrough obesity drug market, providing intelligence across the clinical development and commercial landscapes, as well as wider health economics and outcomes implications.

Airfinity’s Obesity Market Intelligence Solution combines data, technology, and expertise to help you stay ahead of critical developments and inform your ongoing clinical and commercial strategies.

Regular Deep Dive Analysis: High impact analysis on critical Obesity ​topic by expert analysts, e.g. cost to ​prevent CV event comparing AOMs​ to bariatric surgery & CV drugs​

Weekly Newsletter: A specially curated, editorialised summary of critical news across the market, with highlights from Airfinity’s latest analysis.

Intelligence platform: The first ever obesity market platform provides ppeline, competitor, disease, and commercial insights, accessible 24/7 with extensive filters.

Intelligence Alerts: Real time analysis of critical news such as key product launch or pivotal results​ delivered directly to your inbox and available via the platform.

Analyst Access: Get direct access to Airfinity market experts, including a customised monthly briefing​ for your entire team.

Together we will navigate the uncertain through comprehensive tracking, simulation, and forecasting.

Request your free briefing

Fill out this short form and a member of the team will be in touch. Alternatively, you can reach out directly via cardiovascular@airfinity.com.

What our users say?

who

“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”

Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister

hm government

“Airfinity has been instrumental in our country's COVID response.”

Head of UK Government
Vaccine Task Force

ifpma

In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”

Iskra Reic, Executive Vice-President
Astrazeneca

Oxford

“Probably the most expansive, accurate and helpful of the multiple data sets on an international scale”

Sir John Bell ,
University of Oxford